FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017845963> ?p ?o ?g. }

• W2017845963 endingPage "S139" @default.
• W2017845963 startingPage "S138" @default.
• W2017845963 abstract "Purpose/Objective(s)The practice of treating a solitary pulmonary nodule (SPN) suspicious for stage I NSCLC with stereotactic ablative radiation therapy (SABR) in the absence of pathologic confirmation of malignancy is becoming more common. In the absence of randomized evidence, the appropriate lung cancer prevalence threshold of when such a strategy is warranted can be informed using a decision modeling approach.Materials/MethodsA decision tree and Markov model were constructed to evaluate the relative merits of observation, performing SABR without pathology, or performing a biopsy prior to SABR, when faced with a non-calcified SPN > 1 cm in a 75-year old patient at different lung cancer prevalences. Diagnostic characteristics, lung cancer utilities, as well as disease, treatment, and toxicity parameters were extracted from meta-analyses, guideline-based recommendations, and decision analyses. Toxicity and recurrence rates after SABR were obtained from a prospectively collected database of 382 patients receiving SABR for confirmed or suspected stage I NSCLC. As utilities of early stage lung cancer patients treated with SABR have not been well studied, we employed mapping techniques to generate these from another 382 prospective individually-collected EORTC QLQ-C30 quality of life scores in the database. Deterministic sensitivity analyses on all model inputs were performed to inform the appropriate lung cancer prevalence threshold between treatment strategies. The effects of uncertainty in model parameters were evaluated through probabilistic sensitivity analysis (PSA), a technique in which parameter values are picked at random from a distribution for multiple iterations via Monte Carlo simulations. The model was validated internally with source data and externally with data from the California Cancer Registry. A 5-year time horizon using a cycle length of one month was employed and quality adjusted life years (QALYs) were discounted at a rate of 3%.ResultsAt a lung cancer prevalence of 65%, performing a biopsy was the preferred treatment strategy, yielding 2.640 QALYs, compared to 2.563 and 2.086 for the no biopsy and observation strategies, respectively. The prevalence threshold between observation and performing a biopsy was 17.0%; and between performing SABR without pathology and performing a biopsy prior to SABR was 85.0%. The latter finding was confirmed on PSA (85.2%; 95% CI = 80.0%-87.2%). This predicted lung cancer prevalence threshold was most sensitive to the diagnostic sensitivity of transthoracic biopsy (range: 77.2-94.0%).ConclusionsThis model suggests that if there are concerns about increased morbidity related to biopsy for a SPN in an elderly and frail population, SABR is warranted as a treatment strategy when the prevalence of lung cancer exceeds a point estimate of 85%. Purpose/Objective(s)The practice of treating a solitary pulmonary nodule (SPN) suspicious for stage I NSCLC with stereotactic ablative radiation therapy (SABR) in the absence of pathologic confirmation of malignancy is becoming more common. In the absence of randomized evidence, the appropriate lung cancer prevalence threshold of when such a strategy is warranted can be informed using a decision modeling approach. The practice of treating a solitary pulmonary nodule (SPN) suspicious for stage I NSCLC with stereotactic ablative radiation therapy (SABR) in the absence of pathologic confirmation of malignancy is becoming more common. In the absence of randomized evidence, the appropriate lung cancer prevalence threshold of when such a strategy is warranted can be informed using a decision modeling approach. Materials/MethodsA decision tree and Markov model were constructed to evaluate the relative merits of observation, performing SABR without pathology, or performing a biopsy prior to SABR, when faced with a non-calcified SPN > 1 cm in a 75-year old patient at different lung cancer prevalences. Diagnostic characteristics, lung cancer utilities, as well as disease, treatment, and toxicity parameters were extracted from meta-analyses, guideline-based recommendations, and decision analyses. Toxicity and recurrence rates after SABR were obtained from a prospectively collected database of 382 patients receiving SABR for confirmed or suspected stage I NSCLC. As utilities of early stage lung cancer patients treated with SABR have not been well studied, we employed mapping techniques to generate these from another 382 prospective individually-collected EORTC QLQ-C30 quality of life scores in the database. Deterministic sensitivity analyses on all model inputs were performed to inform the appropriate lung cancer prevalence threshold between treatment strategies. The effects of uncertainty in model parameters were evaluated through probabilistic sensitivity analysis (PSA), a technique in which parameter values are picked at random from a distribution for multiple iterations via Monte Carlo simulations. The model was validated internally with source data and externally with data from the California Cancer Registry. A 5-year time horizon using a cycle length of one month was employed and quality adjusted life years (QALYs) were discounted at a rate of 3%. A decision tree and Markov model were constructed to evaluate the relative merits of observation, performing SABR without pathology, or performing a biopsy prior to SABR, when faced with a non-calcified SPN > 1 cm in a 75-year old patient at different lung cancer prevalences. Diagnostic characteristics, lung cancer utilities, as well as disease, treatment, and toxicity parameters were extracted from meta-analyses, guideline-based recommendations, and decision analyses. Toxicity and recurrence rates after SABR were obtained from a prospectively collected database of 382 patients receiving SABR for confirmed or suspected stage I NSCLC. As utilities of early stage lung cancer patients treated with SABR have not been well studied, we employed mapping techniques to generate these from another 382 prospective individually-collected EORTC QLQ-C30 quality of life scores in the database. Deterministic sensitivity analyses on all model inputs were performed to inform the appropriate lung cancer prevalence threshold between treatment strategies. The effects of uncertainty in model parameters were evaluated through probabilistic sensitivity analysis (PSA), a technique in which parameter values are picked at random from a distribution for multiple iterations via Monte Carlo simulations. The model was validated internally with source data and externally with data from the California Cancer Registry. A 5-year time horizon using a cycle length of one month was employed and quality adjusted life years (QALYs) were discounted at a rate of 3%. ResultsAt a lung cancer prevalence of 65%, performing a biopsy was the preferred treatment strategy, yielding 2.640 QALYs, compared to 2.563 and 2.086 for the no biopsy and observation strategies, respectively. The prevalence threshold between observation and performing a biopsy was 17.0%; and between performing SABR without pathology and performing a biopsy prior to SABR was 85.0%. The latter finding was confirmed on PSA (85.2%; 95% CI = 80.0%-87.2%). This predicted lung cancer prevalence threshold was most sensitive to the diagnostic sensitivity of transthoracic biopsy (range: 77.2-94.0%). At a lung cancer prevalence of 65%, performing a biopsy was the preferred treatment strategy, yielding 2.640 QALYs, compared to 2.563 and 2.086 for the no biopsy and observation strategies, respectively. The prevalence threshold between observation and performing a biopsy was 17.0%; and between performing SABR without pathology and performing a biopsy prior to SABR was 85.0%. The latter finding was confirmed on PSA (85.2%; 95% CI = 80.0%-87.2%). This predicted lung cancer prevalence threshold was most sensitive to the diagnostic sensitivity of transthoracic biopsy (range: 77.2-94.0%). ConclusionsThis model suggests that if there are concerns about increased morbidity related to biopsy for a SPN in an elderly and frail population, SABR is warranted as a treatment strategy when the prevalence of lung cancer exceeds a point estimate of 85%. This model suggests that if there are concerns about increased morbidity related to biopsy for a SPN in an elderly and frail population, SABR is warranted as a treatment strategy when the prevalence of lung cancer exceeds a point estimate of 85%." @default.
• W2017845963 created "2016-06-24" @default.
• W2017845963 creator A5032441898 @default.
• W2017845963 creator A5036402068 @default.
• W2017845963 creator A5038486476 @default.
• W2017845963 creator A5047573361 @default.
• W2017845963 creator A5055146377 @default.
• W2017845963 creator A5060829314 @default.
• W2017845963 creator A5062485708 @default.
• W2017845963 creator A5066986846 @default.
• W2017845963 creator A5077453712 @default.
• W2017845963 creator A5090288280 @default.
• W2017845963 date "2014-09-01" @default.
• W2017845963 modified "2023-10-16" @default.
• W2017845963 title "When is a Biopsy-Proven Diagnosis Necessary Before Stereotactic Ablative Radiation Therapy for Lung Cancer? A Decision Analysis" @default.
• W2017845963 doi "https://doi.org/10.1016/j.ijrobp.2014.05.597" @default.
• W2017845963 hasPublicationYear "2014" @default.
• W2017845963 type Work @default.
• W2017845963 sameAs 2017845963 @default.
• W2017845963 citedByCount "0" @default.
• W2017845963 crossrefType "journal-article" @default.
• W2017845963 hasAuthorship W2017845963A5032441898 @default.
• W2017845963 hasAuthorship W2017845963A5036402068 @default.
• W2017845963 hasAuthorship W2017845963A5038486476 @default.
• W2017845963 hasAuthorship W2017845963A5047573361 @default.
• W2017845963 hasAuthorship W2017845963A5055146377 @default.
• W2017845963 hasAuthorship W2017845963A5060829314 @default.
• W2017845963 hasAuthorship W2017845963A5062485708 @default.
• W2017845963 hasAuthorship W2017845963A5066986846 @default.
• W2017845963 hasAuthorship W2017845963A5077453712 @default.
• W2017845963 hasAuthorship W2017845963A5090288280 @default.
• W2017845963 hasBestOaLocation W20178459631 @default.
• W2017845963 hasConcept C126838900 @default.
• W2017845963 hasConcept C143998085 @default.
• W2017845963 hasConcept C19527891 @default.
• W2017845963 hasConcept C19617505 @default.
• W2017845963 hasConcept C2775934546 @default.
• W2017845963 hasConcept C2776256026 @default.
• W2017845963 hasConcept C2778256017 @default.
• W2017845963 hasConcept C2780387249 @default.
• W2017845963 hasConcept C509974204 @default.
• W2017845963 hasConcept C71924100 @default.
• W2017845963 hasConceptScore W2017845963C126838900 @default.
• W2017845963 hasConceptScore W2017845963C143998085 @default.
• W2017845963 hasConceptScore W2017845963C19527891 @default.
• W2017845963 hasConceptScore W2017845963C19617505 @default.
• W2017845963 hasConceptScore W2017845963C2775934546 @default.
• W2017845963 hasConceptScore W2017845963C2776256026 @default.
• W2017845963 hasConceptScore W2017845963C2778256017 @default.
• W2017845963 hasConceptScore W2017845963C2780387249 @default.
• W2017845963 hasConceptScore W2017845963C509974204 @default.
• W2017845963 hasConceptScore W2017845963C71924100 @default.
• W2017845963 hasIssue "1" @default.
• W2017845963 hasLocation W20178459631 @default.
• W2017845963 hasOpenAccess W2017845963 @default.
• W2017845963 hasPrimaryLocation W20178459631 @default.
• W2017845963 hasRelatedWork W1939523200 @default.
• W2017845963 hasRelatedWork W2038159780 @default.
• W2017845963 hasRelatedWork W2093820121 @default.
• W2017845963 hasRelatedWork W2286718711 @default.
• W2017845963 hasRelatedWork W2358208436 @default.
• W2017845963 hasRelatedWork W2359490652 @default.
• W2017845963 hasRelatedWork W24939189 @default.
• W2017845963 hasRelatedWork W2494483646 @default.
• W2017845963 hasRelatedWork W2610426596 @default.
• W2017845963 hasRelatedWork W3131390406 @default.
• W2017845963 hasVolume "90" @default.
• W2017845963 isParatext "false" @default.
• W2017845963 isRetracted "false" @default.
• W2017845963 magId "2017845963" @default.
• W2017845963 workType "article" @default.